Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients

Renal Failure

Volumn 34, Issue 9, 2012, Pages 1123-1128

  Rahimi Ardabili, Babak ^a   Argani, Hassan ^b   Ghorbanihaghjo, Amir ^c   Rashtchizadeh, Nadereh ^c   Naghavi Behzad, Mohammad ^d   Ghorashi, Sona ^e   Nezami, Nariman ^f  

^a UNIVERSITY OF TABRIZ   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Research Committee Tabriz   (Iran)

^e ISLAMIC AZAD UNIVERSITY   (Iran)

^f TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apolipoprotein A; Hemodialysis; High density lipoprotein; Low density lipoprotein; Paraoxonase; Zinc

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; STARCH; TRIACYLGLYCEROL; ZINC SULFATE;

ADULT; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CHRONIC GLOMERULONEPHRITIS; CHRONIC INTERSTITIAL NEPHROPATHY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET SUPPLEMENTATION; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; IMMUNOTURBIDIMETRY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TURBIDIMETRY; URINARY TRACT DISEASE; ZINC BLOOD LEVEL;

APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SPECTROPHOTOMETRY, ATOMIC; TREATMENT OUTCOME; ZINC;

EID: 84866397972     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.717479     Document Type: Article

References (63)

1. Bevc S, Sabic S, Hojs R. Atherosclerosis in hemodialysis patients - the role of microinflammation. Ren Fail. 2008; 30(10):1012-1016.
2. Houtman JP. Trace elements and cardiovascular diseases. J Cardiovasc Risk. 1996;3(1):18-25.
3. Aalbers TG, Houtman JP. Relationships between trace elements and atherosclerosis. Sci Total Environ. 1985;43(3):255-283.
4. Brewer LC, Michos ED, Reis JP. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets. 2011;12(1):54-60.
5. Chitalia N, Recio-Mayoral A, Kaski JC, Banerjee D. Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis. 2012;220(1):265-268.
6. Cozzolino M, Ketteler M, Zehnder D. The vitamin D system: A crosstalk between the heart and kidney. Eur J Heart Fail. 2010;12(10):1031-1041.
7. Rossowska MJ, Ghanaei P, Nakamoto T. Effect of dietary caffeine and zinc on the activity of antioxidant enzymes, zinc, and copper concentration of the heart and liver in fast-growing rats. Biol Trace Elem Res. 1995;50(3):229-236.
8. Noleto Magalhaes RC, Guedes Borges de Araujo C, Batista de Sousa Lima V, Machado Moita Neto J, do Nascimento Nogueira N, do Nascimento Marreiro D. Nutritional status of zinc and activity superoxide dismutase in chronic renal patients undergoing hemodialysis. Nutr Hosp. 2011;26(6):1456-1461.
9. Ongajooth L, Ongajyooth S, Likidlilid A, Chantachum Y, Shayakul C, Nilwarangkur S. Role of lipid peroxidation, trace elements and anti-oxidant enzymes in chronic renal disease patients. J Med Assoc Thai. 1996;79(12):791-800.
10. Koca T, Berber A, Koca HB, Demir TA, Koken T. Effects of hemodialysis period on levels of blood trace elements and oxidative stress. Clin Exp Nephrol. 2010;14(5):463-468.
11. Wratten ML, Galaris D, Tetta C, Sevanian A. Evolution of oxidative stress and inflammation during hemodialysis and their contribution to cardiovascular disease. Antioxid Redox Signal. 2002;4(6):935-944.
12. Ivanovski O, Nikolov IG, Drueke BT, Massy AZ. Atherosclerosis and vascular calcification in uraemia - a new experimental model. Prilozi. 2007;28(2):11-24.
13. Segarra A, Chacon P, Martin M, et al. Serum lipoprotein (a) levels in patients with chronic renal failure - evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: A prospective study. Nephron. 1995; 69(1):9-13.
14. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21(6):573-592.
15. Maheshwari N, Ansari MR, Darshana MS, Lal K, Ahmed K. Pattern of lipid profile in patients on maintenance hemodialysis. Saudi J Kidney Dis Transpl. 2010;21(3):565-570.
16. Tepel M, Echelmeyer M, Orie NN, Zidek W. Increased intracellular reactive oxygen species in patients with end-stage renal failure: Effect of hemodialysis. Kidney Int. 2000;58(2):867-872.
17. Bonomini M, Stuard S, Carreno MP, et al. Neutrophil reactive oxygen species production during hemodialysis: Role of activated platelet adhesion to neutrophils through P-selectin. Nephron. 1997;75(4):402-411.
18. Nunez-Cordoba JM, Martinez-Gonzalez MA. Antioxidant vitamins and cardiovascular disease. Curr Top Med Chem. 2011;11(14):1861-1869.
19. Meurs I, Van Eck M, Van Berkel TJ. High-density lipoprotein: Key molecule in cholesterol efflux and the prevention of atherosclerosis. Curr Pharm Des. 2010;16(13):1445-1467.
20. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8(4):222-232.
21. Shamir R, HartmanC, Karry R, et al. Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: Selective secretion of PON1 and PON2. Free Radic Biol Med. 2005;39(3):336-344.
22. Forte TM, Oda MN, Knoff L, et al. Targeted disruption of the murine lecithin: Cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. J Lipid Res. 1999;40(7):1276-1283.
23. Fuhrman B, Volkova N, Aviram M. Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis. 2005; 180(1):55-61.
24. Deakin S, Moren X, James RW. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis. 2005;179(1):17-25.
25. Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000;101(21): 2510-2517.
26. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96(6):2882-2891.
27. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by highdensity lipoprotein associated paraoxonase. Atherosclerosis. 1993;104(1-2):129-135.
28. Kaplan M, Aviram M. Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med. 1999;37(8):777-787.
29. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: Studies in PON1-knockout mice. Free Radic Biol Med. 2003;34(6):774-784.
30. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant ofmacrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis. 2006;187(1):74-81.
31. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem. 1986;32(4):671-673.
32. MacKness B, Mackness MI, Durrington PN, et al. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest. 2000;30(1):4-10.
33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
34. Abuja PM, Albertini R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta. 2001;306(1-2):1-17.
35. Bao B, Prasad AS, Beck FW, et al. Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: A potential implication of zinc as an atheroprotective agent. Am J Clin Nutr. 2010;91(6):1634-1641.
36. Jenner A, Ren M, Rajendran R, et al. Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet. Free Radic Biol Med. 2007;42(4):559-566.
37. Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J, Vaussenat F. Imbalance of oxidants and antioxidants in hemodialysis patients. Blood Purif. 1999;17(2-3):99-106.
38. Rysz J, Potargowicz E, Banach M, et al. Increased whole blood chemiluminescence in patients with chronic renal failure independent of hemodialysis treatment. Arch Immunol Ther Exp (Warsz). 2006;54(5):347-355.
39. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62(5):1524-1538.
40. Drueke TB, Nguyen Khoa T, Massy ZA, Witko-Sarsat V, Lacour B, Descamps-Latscha B. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int Suppl. 2001;78:S114-S119.
41. Mitra S, Deshmukh A, Sachdeva R, Lu J, Mehta JL. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am J Med Sci. 2011;342(2):135-142.
42. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84(4):1381-1478.
43. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: Focus on antioxidative activities. Curr Opin Lipidol. 2010;21(4):312-318.
44. Shoji T, Nishizawa Y. Plasma lipoprotein abnormalities in hemodialysis patients - clinical implications and therapeutic guidelines. Ther Apher Dial. 2006;10(4):305-315.
45. Kushiya F, Wada H, Sakakura M, et al. Effects of lipid abnormalities on arteriosclerosis and hemostatic markers in patients under hemodialysis. Clin Appl Thromb/Hemost. 2003; 9(3):203-210.
46. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JA. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 1994;33(3):832-839.
47. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem/FEBS. 1993;211(3):871-879.
48. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(4): 473-480.
49. Sumegova K, Blazicek P, Waczulikova I, Zitnanova I, Durackova Z. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks. Acta Biochim Pol. 2006;53(4):783-787.
50. AviramM, Kaplan M, RosenblatM, Fuhrman B. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handb Exp Pharmacol. 2005;170:263-300.
51. Ikeda Y, Suehiro T, Itahara T, et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol. 2007;67(6):358-365.
52. Saeed SA, Elsharkawy M, Elsaeed K, Fooda O. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int. 2008;12(4):471-479.
53. Suehiro T, Ikeda Y, Shiinoki T, et al. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb. 2002;9(3):133-138.
54. Itahara T, Suehiro T, Ikeda Y, et al. Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb. 2000;7(3):152-158.
55. Lahrach H, Ghalim N, Taki H, et al. Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis. J Clin Lipidol. 2008;2(1):43-50.
56. Kotur-Stevuljevic J, Simic-Ogrizovic S, Dopsaj V, et al. A hazardous link between malnutrition, inflammation and oxidative stress in renal patients. Clin Biochem. 2012. Available at: Http:// linkinghub.elsevier.com/retrieve/pii/ S0009-9120%2812% 2900206-8. Accessed August 18, 2012.
57. Navarro-Alarcon M, Reyes-Perez A, Lopez-Garcia H, Palomares-Bayo M, Olalla-Herrera M, Lopez-Martinez MC. Longitudinal study of serum zinc and copper levels in hemodialysis patients and their relation to biochemical markers. Biol Trace Elem Res. 2006;113(3):209-222.
58. Szpanowska-Wohn A, Kolarzyk E, Chowaniec E. Estimation of intake of zinc, copper and iron in the diet of patients with chronic renal failure treated by hemodialysis. Biol Trace Elem Res. 2008;124(2):97-102.
59. Zwolinska D, Grzeszczak W, Kilis-Pstrusinska K, Szprynger K, Szczepanska M. Lipid peroxidation and antioxidant enzymes in children with chronic renal failure. Pediatr Nephrol. 2004;19 (8):888-892.
60. Yanagisawa H. Zinc deficiency and clinical practice - validity of zinc preparations. Yakugaku Zasshi. 2008;128(3):333-339.
61. BarcelouxDG. Zinc. J Toxicol Clin Toxicol. 1999;37(2): 279-292.
62. Wratten ML, Tetta C, Ursini F, Sevanian A. Oxidant stress in hemodialysis: Prevention and treatment strategies. Kidney Int Suppl. 2000;76:S126-S132.
63. Powell SR. The antioxidant properties of zinc. J Nutr. 2000;130 (5S Suppl):1447S-1454S.